Table 1.
Baseline demographic and clinical characteristics (per protocol set)
| MSB11022 (n = 203) | Reference adalimumab (n = 191) | |
|---|---|---|
| Male, n (%) | 136 (67·0) | 130 (68·1) |
| Age (years), mean ± SD | 44·8 ± 12·7 | 42·4 ± 11·8 |
| Race, n (%) | ||
| White | 192 (94·6) | 179 (93·7) |
| Black | 1 (0·5) | 0 |
| Asian | 3 (1·5) | 8 (4·2) |
| American Indian or Alaska native | 7 (3·4) | 4 (2·1) |
| Region, n | Both arms | |
| Europe | 326 | |
| Americas | 68 | |
| Weight (kg), mean ± SD | 81·4 ± 13·5 | 80·0 ± 13·1 |
| Body mass index (kg m−2) | ||
| Mean ± SD | 26·6 ± 3·1 | 26·3 ± 3·0 |
| Median (interquartile range) | 27·6 (24·2–29·1) | 26·8 (24·2–29·1) |
| PASI | ||
| Mean ± SD | 20·6 ± 8·8 | 21·2 ± 8·1 |
| Median (range) | 17·4 (12·0–61·8) | 18·4 (12·1–48·2) |
| BSA affected (%) | ||
| Mean ± SD | 28·6 ± 14·3 | 29·9 ± 13·6 |
| Median (range) | 25·9 (11·0–86·0) | 27·1 (10·0–72·0) |
| PGA, n (%) | ||
| Moderate | 146 (71·9) | 128 (67·0) |
| Severe | 57 (28·1) | 63 (33·0) |
| Previous biologic or other therapy for psoriasis, n (%) | 177 (87·2) | 168 (88·0) |
| Previous biologic or other therapy, n (%) | ||
| Etanercept | 22 (10·8) | 24 (12·6) |
| Infliximab | 2 (1·0) | 1 (0·5) |
| Other | 175 (86·2) | 166 (86·9) |
PASI, Psoriasis Area and Severity Index; BSA, body surface area; PGA, Physician's Global Assessment.